14 completed. 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 14 |
Follow Gastrinoma: new trials by email Literature Review of Gastrinoma trials Research Report on Gastrinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors regorafenib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | University of Southern California | 3 | 2016-08-16 | 2021-12-15 |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors temozolomide, capecitabine - Gastrinoma, Glucagonoma | Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 144 | 2013-08-08 | 2026-09-29 |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Capecitabine, Temozolomide, Bevacizumab - Gastrinoma, Glucagonoma | Phase 2 | Completed | Shaheen Shagufta | 20 | 2012-12-01 | 2024-02-06 |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors AMG 706, octreotide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Eastern Cooperative Oncology Group | 46 | 2008-11-07 | 2023-07-05 |
| Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors capecitabine, cisplatin, streptozocin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 84 | 2005-08-01 | 2013-08-07 |
| Capecitabine and Temozolomide for Neuroendocrine Cancers Capecitabine, Temozolomide - Neuroendocrine Tumors | Phase 2 | Completed | Columbia University | 41 | 2005-08-01 | 2016-07-25 |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors sorafenib tosylate - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2005-06-01 | 2014-11-17 |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery fluorouracil, irinotecan hydrochloride, leucovorin calcium - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 20 | 2004-05-01 | 2016-05-30 |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors gefitinib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 90 | 2003-12-01 | 2013-06-04 |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors EPO906 epothilone B - Carcinoid, Neuroendocrine Tumors | Phase 2 | Completed | Novartis Pharmaceuticals | 33 | 2002-07-01 | 2017-03-01 |
| PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors bortezomib - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 2001-04-01 | 2013-01-31 | |
| Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors thalidomide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2001-03-01 | 2013-06-18 | |
| The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Pantoprazole, Omeprazole - Gastrinoma, Zollinger Ellison Syndrome | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1983-02-03 | 2017-07-02 | |
| Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin - Islet Cell Adenoma, Neoplasm Metastasis | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 999 | 1978-09-01 | 2008-03-04 |
Somatostatinoma (11) · Glucagonoma (10) · Insulinoma (10) · Carcinoma, Islet Cell (9) · Adenoma, Islet Cell (7) · Vipoma (7) · Neoplasms (4) · Neuroendocrine Tumors (4) · Zollinger-Ellison Syndrome (3) · Carcinoid Tumor (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Carcinoma (1) · Carcinoma, Medullary (1)
Adenocarcinoma (14) · Digestive System Diseases (14) · Digestive System Neoplasms (14) · Endocrine Gland Neoplasms (14) · Endocrine System Diseases (14) · Neoplasms by Histologic Type (14) · Neoplasms by Site (14) · Neoplasms, Glandular and Epithelial (14) · Pancreatic Diseases (14) · Carcinoma (13) · Carcinoma, Neuroendocrine (12) · Neoplasms, Germ Cell and Embryonal (12) · Neuroectodermal Tumors (12) · Pancreatic Neoplasms (12) · Adenoma (11)
Capecitabine (4) · Temozolomide (3) · Fluorouracil (2) · Streptozocin (2) · Bevacizumab (1) · Bortezomib (1) · Cisplatin (1) · Doxorubicin (1) · Gefitinib (1) · Irinotecan (1) · Leucovorin (1) · Octreotide (1) · Omeprazole (1) · Pantoprazole (1) · Sorafenib (1)
National Cancer Institute (NCI) (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Cambridge University Hospitals NHS Foundation Trust (1) · Columbia University (1) · ECOG-ACRIN Cancer Research Group (1) · Eastern Cooperative Oncology Group (1) · Federation Francophone de Cancerologie Digestive (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · Ohio State University Comprehensive Cancer Center (1) · Shaheen Shagufta (1) · University of Southern California (1)
United States (12) · United Kingdom (1)
Timothy Hobday (2) · Guillaume Cadiot (1) · Leonard B. Saltz, MD (1) · Manisha H. Shah, MD (1) · Mary Mulcahy, MD (1) · Pamela Kunz (1) · Paul E Oberstein, MD (1) · Pippa Corrie, PhD, FRCP (1) · Shaheen Shagufta, MD (1) · Syma Iqbal, MD (1) · Tim Meyer, MD, BSc, MRCP, PhD (1)
PMID 21831734, PMID 29853660, PMID 36260828
N01CM62205 (2), P30CA014089 (1), U10CA021115 (1), U10CA023318 (1), U10CA180820 (1)